Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG have gained a world-first regulatory approval for the use of a CRISPR-based gene editing therapy in patients, as the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorisation for CASGEVY.[1],[2] CASGEVY is a therapy designed to treat sickle-cell disease and inherited blood disorders, and works …
>> Read more